Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BioAtla ( (BCAB) ) just unveiled an update.
On December 30–31, 2025, BioAtla, Inc. announced an agreement under which Inversagen AI, LLC, backed by GATC Health Corp and Alliance International Resources Corp., will invest a total of $40 million in a special purpose vehicle (BA 3021 SPV LLC) holding the oncology rights to BioAtla’s Phase 3-stage asset ozuriftamab vedotin (Oz‑V), in exchange for a 35% stake in the SPV, leaving BioAtla with 65% ownership. The deal, structured as a private placement across two closings expected to occur by the end of the first quarter of 2026, will provide BioAtla with an initial $5 million and a further $35 million to fund general operations and a registrational Phase 3 trial of Oz‑V in second-line or later oropharyngeal squamous cell carcinoma (OPSCC), with BioAtla retaining leadership of trial execution through potential accelerated approval and positioning the company to expand Oz‑V into HPV-positive solid tumors while sharing future development and commercialization costs with Inversagen AI.
The most recent analyst rating on (BCAB) stock is a Hold with a $0.78 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.
Spark’s Take on BCAB Stock
According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.
The score is held down primarily by weak financial performance—no TTM revenue, persistent large losses and cash burn, and a move to negative equity. The earnings call adds support from meaningful clinical/regulatory progress and potential partnering, but low cash and rising quarterly net loss temper that. Technicals are mixed-to-neutral, and valuation is unattractive due to ongoing losses and no dividend.
To see Spark’s full report on BCAB stock, click here.
More about BioAtla
BioAtla, Inc. is a global clinical-stage biotechnology company listed on Nasdaq and focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. Using its proprietary CAB platform, the company designs reversibly active monoclonal and bispecific antibodies and other protein therapeutics intended to improve selectivity, efficacy and safety over traditional antibodies, supported by extensive worldwide patent coverage across major markets.
Average Trading Volume: 1,528,143
Technical Sentiment Signal: Hold
Current Market Cap: $46.27M
See more insights into BCAB stock on TipRanks’ Stock Analysis page.